Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Japan Reconsiders Online, Mail-Order Sales Ban Of Risky Drugs

This article was originally published in PharmAsia News

Executive Summary

Japan had planned to ban online sales of nonprescription drugs deemed to have a moderate to high risk of side effects, but now is reconsidering. The Health, Labor and Welfare Ministry had said earlier the ban would include mail-order sales as well, but it still needs to form a committee to consider whether the proposal is appropriate. Internet retailers, the disabled and the general public raised such an outcry the ministry agreed to review its plan to enact the ban June 1. In addition to considering a ban, the panel also is to study other ways to address the problem of unsafe drugs sold from remote sites. The Japan Pharmaceutical Association supports a ban. (Click here for more - a subscription may be required

You may also be interested in...



Japan's BioComo Pursues Novel Ligand Approach To Immuno-Oncology

Japan bioventure BioComo was set up around 10 years ago and has since been honing its technology platform. It is now preparing to move into the clinic with a novel vector for immuno-oncology and to raise new funds to support pipeline development.

China Uses Old To Fight New As Repurposed Drugs Take Coronavirus Role

Several newly repurposed drugs, including a Bayer antimalarial, have shown potential benefits against the new coronavirus, promoting China to add several to its latest revised treatment guidelines.

US FDA Still Seeking Sponsor Cooperation For Oncology Label Updates

Oncology Center of Excellence is reviewing a research report on fluorouracil, and will next look to update cisplatin's label, but eventually must convince the reference product sponsor to submit the changes.

UsernamePublicRestriction

Register

SC070982

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel